We depend on your feedback to maintain a high-quality resource for information about Rhophylac^®. You may use the form below or contact us by telephone.

CSL Behring LLC
Address: P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA
Phone: 610-878-4000
Fax: 610-878-4009

Customer Service
Phone: 800-655-3396
Fax: 610-878-4888

Medical Affairs
Phone: 800-504-5434
Fax: 610-878-4007

Report Adverse Events
Phone: 610-878-4193
After Hours: 800-504-5434

* To ensure that your question or comment is directed to the appropriate CSL Behring department, please select one of these choices.


*	I am a:

*	First Name:
*	Last Name:

*	This is my	Home address Work address
*	Address 1:
	Address 2:
*	City:
*	State:
*	ZIP Code:
*	E-mail Address:
*	Confirm E-mail Address:
	Telephone Number: (include area code)
	Fax Number: (include area code)

	Comments:
	I would like a CSL Behring representative to contact me by: Phone E-mail
	I would like eNews updates so I can get the latest information about HDN and Rhophylac^® as it becomes available. (Note: You will have the option to opt-out from receiving CSL Behring e-mails if you choose to do so in the future.)

	Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Rhophylac^® is indicated for suppression of rhesus (Rh) isoimmunization in:

Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isommunization, Rhophylac^® can be administered IM or IV.

Rhophylac^® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac^®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For postpartum use following an Rh-incompatible pregnancy, Rhophylac^® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac^® are nausea, dizziness, headache, injection-site pain, and malaise.

Please see full prescribing information.